Eli Lilly’s Ebglyss achieved ‘deep and sustained response’ in ADjoin study

New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis at three years. These findings from the ADjoin long-term extension study will be presented at the American Academy of Dermatology Annual Meeting, taking place March 7-11 in Orlando. Ebglyss is an interleukin-13 inhibitor that selectively blocks IL-13 signaling with high binding affinity. The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection. Of the patients who responded to treatment at Week 16 and were receiving once-monthly maintenance dosing, 50% of patients achieved complete skin clearance at three years. Additionally, 87% achieved or maintained almost-clear skin at three years. Over 83% of Week 16 responders taking Ebglyss did not require the use of concomitant therapies such as topical corticosteroids or topical calcineurin inhibitors for the duration of the ADjoin study.